Biohaven Pharmaceutical Holding Net Profit Margin 2016-2022 | BHVN

Current and historical net profit margin for Biohaven Pharmaceutical Holding (BHVN) from 2016 to 2022. Net profit margin can be defined as net Income as a portion of total sales revenue. Biohaven Pharmaceutical Holding net profit margin for the three months ending March 31, 2022 was .
Biohaven Pharmaceutical Holding Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2022-03-31 $0.74B $-0.79B -107.18%
2021-12-31 $0.46B $-0.85B -182.94%
2021-09-30 $0.31B $-0.87B -281.17%
2021-06-30 $0.19B $-0.89B -467.89%
2021-03-31 $0.11B $-0.86B -802.80%
2020-12-31 $0.06B $-0.77B -1198.44%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $9.948B $0.463B
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.724B 9.84
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.093B 15.93
Ginkgo Bioworks Holdings (DNA) United States $4.434B 0.00
Emergent Biosolutions (EBS) United States $1.592B 6.82
Arcus Biosciences (RCUS) United States $1.327B 33.64
Myovant Sciences (MYOV) United Kingdom $0.961B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.483B 0.00
Gelesis Holdings (GLS) United States $0.357B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.117B 24.00
SQZ Biotechnologies (SQZ) United States $0.092B 0.00